In addition, a mass of dual cascade-targeting drug delivery systems including daunorubicin-loaded liposome conjugated with p-aminophenyl-α-d-manno-pyranoside (MAN) and Tf, liposome co-modified with T7 and TAT, have been proved to possess stronger BBB-crossing and glioma-accumulating capability compared with single ligand-modified systems [98,105]. The gene discussed is TF; the disease is glioma.